共 50 条
Lipid-Based Nanocarriers via Nose-to-Brain Pathway for Central Nervous System Disorders
被引:31
|作者:
Thuy Trang Nguyen
[1
]
Thi Thuy Dung Nguyen
[2
]
Nguyen-Minh-An Tran
[3
]
Giau Van Vo
[4
,5
,6
]
机构:
[1] Ho Chi Minh City Univ Technol HUTECH, Fac Pharm, Ho Chi Minh City 700000, Vietnam
[2] Nguyen Tat Thanh Univ, Fac Environm & Food Engn, Ho Chi Minh City 700000, Vietnam
[3] Ind Univ Ho Chi Minh City, Fac Chem Engn, Ho Chi Minh City 71420, Vietnam
[4] Vietnam Natl Univ Ho Chi Minh City VNU HCM, Sch Med, Dept Biomed Engn, Ho Chi Minh City 700000, Vietnam
[5] Vietnam Natl Univ Ho Chi Minh City VNU HCM, Res Ctr Genet & Reprod Hlth CGRH, Sch Med, Ho Chi Minh City 700000, Vietnam
[6] Vietnam Natl Univ Ho Chi Minh City VNU HCM, Ho Chi Minh City 700000, Vietnam
关键词:
Neurodegenerative diseases;
Intranasal delivery;
Lipid nanocarriers;
Brain targeting;
Nose-to-brain;
CONTROLLED DRUG-DELIVERY;
SITU NASAL GEL;
IN-VIVO;
INTRANASAL DELIVERY;
NANOPARTICLES SLN;
CORE NANOCAPSULES;
THERAPEUTIC STRATEGIES;
EX-VIVO;
CARRIERS;
FORMULATION;
D O I:
10.1007/s11064-021-03488-7
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
Neurodegenerative disorders are distinguished by the gradual deterioration of the nervous system's structure and function due to oxidative stress, mitochondrial dysfunction, protein misfolding, excitotoxicity, and neuroinflammation. Among these NDs, Alzheimer's disease, Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis characterized an increasing dysfunction and loss of neuronal structure leading to neuronal cell death. Although there is currently no drug to totally reverse the effects of NDs, such novel formulations and administration routes are developed for better management and nose-to-brain delivery is one of delivery for treating NDs. This review aimed to highlight advances in research on various lipid based nanocarriers such as liposomes, solid lipid nanoparticles, nanostructured lipid carriers, microemulsion, nanoemulsion, and cubosomes which are reported to treat and alleviate the symptoms of NDs via nose-to-brain route. The challenges during clinical translation of lipid nanocarriers from bench to bed side is also discussed.
引用
收藏
页码:552 / 573
页数:22
相关论文